Scholar Rock Holding Corp (SRRK) Q3 2025 10-Q Quarterly Report
Filed: Nov 14, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Scholar Rock Holding Corp (SRRK) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 14, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Scholar Rock Holding Corp Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • No off-balance sheet arrangements during periods presented
- • Recent accounting standards reviewed; no material impact identified
Risk Factors
- • New risk: FDA CRL in Sept 2025 on third-party fill-finish facility delays apitegromab BLA resubmission and commercialization progress
- • Material update: Impact of 2025 U.S. govt staffing cuts reduces FDA review capacity, risking further regulatory delays for apitegromab
Scholar Rock Holding Corp Q3 2025 Quarterly FinancialsXBRL
Revenue
$0
Net Income
-$102M
▼ -58.5% YoY▲ +7.1% QoQ
ROE
-41.7%
Total Assets
$412M
EPS (Diluted)
$-0.89
▼ -34.8% YoY▲ +9.2% QoQ
Operating Cash Flow
-$69M
▼ -31.4% YoY▲ +10.4% QoQ
Source: XBRL data from Scholar Rock Holding Corp Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Scholar Rock Holding Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.